References
- The Writing Group for the PEP Trial. Effects of estrogen or estrogen progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen Progestin Inter-ventions (PEP!) Trial. JAm Med Assoc 1995;273: 199–208
- Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Post-menopausal estrogen use and mortality. Results from a prospective study in a defined, homo-geneous community. Am J Epidemiol 1988;128: 606–14
- Schaad MA, Bonjour JP, Rizzoli R. Evaluation of hormone replacement therapy use by the sales figures. Maturitas 2000;34:185–91
- Nagata C, Matsushita Y, Shimizu H. Prevalence of hormone replacement therapy and user's characteristics: a community survey in Japan. Maturitas 1996;25:201–7
- Collins JA, Schulesselman JJ. Hormone replace-ment therapy and endometrial cancer. In: Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 1999:503–11
- Hill DA, Weiss NS, Beresford SA, et al. Continu-ous combined hormone replacement therapy and risk of endometrial cancer. Obstet Gyne col 2000; 183:1456–61
- Reports of Gynecologic Oncology Committee. Acta Obstet Gynecol Jpn 2000;52:699–733
- Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304–13
- The Writing Group for the PEP Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Post-menopausal Estrogen Progestin Interventions (PEP!) Trial. J Am Med Assoc 1996;275:370–5
- Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replace-ment with and without progestins. J Natl Cancer Inst 1999;91:1131–7
- Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women Lancet 1997; 349:458–61
- Pike MC, Peters RK, Cozen W, et al. Estrogen—progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89: 1110–16
- Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case—control study. Lancet 1999;353: 1824–8